| Description | Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). |
| In vitro | Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K/Akt signaling pathway. It may cause inhibition of tumor cell growth and survival in susceptible tumor cell populations [3]. |
| Target activity | p120γ:1 nM, p110α:0.1 nM, p110δ:2.9 nM |
| Synonyms | PX-866 |
| molecular weight | 525.59 |
| Molecular formula | C29H35NO8 |
| CAS | 502632-66-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Ihle NT, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growthfactor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther. 2005 Sep;4(9):1349-57. 2. Bowles DW, et al. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2. 3. Sonolisib |